Research and development
pipeline

Our research and development pipeline covers therapeutic areas with high unmet need.

Ophthalmology

NERVE GROWTH FACTOR (NGF)

Discovered in the 1950s by Rita Levi Montalcini, the Nerve Growth Factor (NGF) is a neurotrophin - a family of proteins that can play a key role in regulating the survival, growth and differentiation of neurons, both at a central and peripheral level.¹

The potential of the NGF in ophthalmology has been studied in depth by researchers at Anabasis, an Italian research company that merged with Dompé, subsequently developing an NGF ophthalmic formulation for clinical studies of various ophthalmic diseases.

¹Mastropasqua L, Massaro-Giordano G, Nubile M, Sacchetti M. Understanding the pathogenesis of neurotrophic keratitis: the role of corneal nerves. J Cell Physiol. 2017;232:717-724.

RHNGF
DRY EYE SYNDROME

  • DISCOVERY

  • PRECLINICAL

  • PHASE I

  • PHASE II

  • PHASE III

RHNGF
GLAUCOMA

  • DISCOVERY

  • PRECLINICAL

  • PHASE I

  • PHASE II

  • PHASE III

Diabetes

LADARIXIN

Ladarixin is an inhibitor of IL-8 activity, and is being evaluated for its role in modulating the autoimmune mediated inflammatory cascade that leads to the onset and progression of type 1 diabetes.¹

¹ Citro A, Valle A, Cantarelli E, et al. CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice. Diabetes. 2015;64(4):1329-1340. doi:10.2337/db14-0443

LADARIXIN
TYPE 1 DIABETES ONSET

  • DISCOVERY

  • PRECLINICAL

  • PHASE I

  • PHASE II

  • PHASE III

Severe COVID-19 Pneumonia, Metastatic Triple Negative Breast Cancer, Transplant

REPARIXIN

Reparixin is an inhibitor of CXCR1 and CXCR2 receptors. It is the first of a new class of low-molecular-weight inhibitors that are thought to selectively modulate the receptor activity through an allosteric mechanism of action.

On May 12, 2020 the Italian Medicines Agency (AIFA), based on pre-clinical and trial safety experience, authorized the commencement of a Phase 2/3 clinical study in Italy, titled REPAVID-19, to evaluate efficacy and safety of reparixin in hospitalized adult patients with severe COVID-19 pneumonia.

REPARIXIN
Metastatic Triple Negative Breast Cancer

  • DISCOVERY

  • PRECLINICAL

  • PHASE I

  • PHASE II

  • PHASE III